EP26 is a potent PD-L1/EGFR Dual Inhibitor with High Druggability for Glioblastoma Immunotherapy. EP26 exhibited the inhibitory activity against EGFR (IC50 = 37.5 nM) and PD-1/PD-L1 interaction (IC50 = 1.77 μM). EP26 displayed superior in vitro antiproliferative activities and in vitro immunomodulatory effects by promoting U87MG cell death in a U87MG/Jurkat cell coculture model. Furthermore, EP26 Possessed favorable pharmacokinetic properties (F = 22%) and inhibited tumor growth (TGI = 92.0%) in a GBM mouse model more effectively than Gefitinib (77.2%) and NP19 (82.8%).
MedKoo Cat#: 126969
Name: EP26
CAS#: N/A
Chemical Formula: C42H42ClFN4O5
Exact Mass: 736.2828
Molecular Weight: 737.27
Elemental Analysis: C, 68.42; H, 5.74; Cl, 4.81; F, 2.58; N, 7.60; O, 10.85
The following data is based on the product molecular weight 737.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
-Xylose0346.jpg "D-(+)-Xylose")
